Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
HIV-1 infection is a manageable chronic condition, with non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs) remaining a cornerstone of antiretroviral therapy. Nevertheless, drug resistance to existing therapeutics is a serious and immediate concern. Using structure-based and scaffold-hopping approaches, we designed evolved diarylpyrimidine analogs targeting reverse transcriptase (RT), exploiting chemical space surrounding the NNRTI-binding pocket. We identified compounds 5i3 and 5e2 , with robust antiviral efficacy against wild-type HIV-1 and rilpivirine-resistant strains. Encouragingly, in vitro selection of mutant strains with 5i3 took 39 passages to select resistance, with no phenotypic cross-resistance observed with known RT drugs. Co-crystal structures of wild-type and mutant RT with 5i3 and 5e2 revealed their resilience toward resistance mutations due to enhanced conformational flexibility and positional adaptability. 5i3 exhibited good pharmacokinetic properties and favorable safety profiles, without substantial cytochrome P450 inhibition, and excellent oral bioavailability. These derivatives represent a promising scaffold for the development of anti-HIV drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NNRTIs inhibit HIV-1 reverse transcriptase (RT) by binding to a specific, non-catalytic hydrophobic pocket known as the non-nucleoside inhibitor binding pocket (NNIBP). This binding site is located approximately 10 Å from the polymerase active site. The interaction induces conformational changes in RT that disrupt its enzymatic function, thereby inhibiting viral DNA synthesis (40, 45).”
From Research progress on HIV-1 structural proteins and antiviral therapies (2026) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Daina, A., Michielin, O., & Zoete, V. (2017) · Scientific Reports · doi:10.1038/srep42717 · Cited by 18,367
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., & De Clercq, E. (1988) · Journal of Virological Methods · doi:10.1016/0166-0934(88)90134-6 · Cited by 1,642
hERG potassium channels and cardiac arrhythmia
Sanguinetti, M. C., & Tristani-Firouzi, M. (2006) · Nature · doi:10.1038/nature04710 · Cited by 1,572
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
(2007) · PubMed · Cited by 953
A structural basis for drug-induced long QT syndrome
Mitcheson, J. S., Chen, J., Lin, M., Culberson, C., & Sanguinetti, M. C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.210244497 · Cited by 944
Polder maps: improving OMIT maps by excluding bulk solvent
Liebschner, D., Afonine, P. V., Moriarty, N. W., Poon, B. K., Sobolev, O. V., Terwilliger, T. C., & Adams, P. D. (2017) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798316018210 · Cited by 657
Efficient Drug Lead Discovery and Optimization
Jorgensen, W. L. (2009) · Accounts of Chemical Research · doi:10.1021/ar800236t · Cited by 649
Das, K., Clark, Lewi, P. J., Heeres, J., de Jonge, M. R., Koymans, L. M. H., Vinkers, H. M., Daeyaert, F., Ludovici, D. W., Kukla, M. J., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030558s · Cited by 514
Self-citationThe structural biology of HIV-1: mechanistic and therapeutic insights
Engelman, A., & Cherepanov, P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2747 · Cited by 424
Evolution of strategies to improve preclinical cardiac safety testing
Gintant, G., Sager, P. T., & Stockbridge, N. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.34 · Cited by 407 · cited 1×
“To assess the hERG-related cardiotoxicity, the hERG potassium channel inhibition assay of 5i3 was performed in Chinese hamster ovary (CHO) cells transfected with hERG cDNA using the electro-physiological manual patch-clamp technique, with RPV as the reference drug ( 53 ).”
Pannecouque, C., Daelemans, D., & De Clercq, E. (2008) · Nature Protocols · doi:10.1038/nprot.2007.517 · Cited by 353
Self-citationDas, K., Bauman, J. D., Clark, A. D., Frenkel, Y. V., Lewi, P. J., Shatkin, A. J., Hughes, S. H., & Arnold, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711209105 · Cited by 343
Self-citationAzijn, H., Tirry, I., Vingerhoets, J., de Béthune, M.-P., Kraus, G., Boven, K., Jochmans, D., Van Craenenbroeck, E., Picchio, G., & Rimsky, L. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00986-09 · Cited by 293
ProteinsPlus: a web portal for structure analysis of macromolecules
Fährrolfes, R., Bietz, S., Flachsenberg, F., Meyder, A., Nittinger, E., Otto, T., Volkamer, A., & Rarey, M. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx333 · Cited by 260
Four decades of HIV/AIDS - much accomplished, much to do
Fauci, A. S., & Lane, H. C. (2020) · New England Journal of Medicine · doi:10.1056/nejmp1916753 · Cited by 199
Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses
Ma, Y., Frutos-Beltrán, E., Kang, D., Pannecouque, C., De Clercq, E., Menéndez-Arias, L., Liu, X., & Zhan, P. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01084g · Cited by 198
Self-citationThe Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance
Hsiou, Y., Ding, J., Das, K., Clark, A. D., Boyer, P. L., Lewi, P., Janssen, P. A. J., Kleim, J.-P., Rösner, M., Hughes, S. H., et al. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4648 · Cited by 195
Self-citationThe Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic
Namasivayam, V., Vanangamudi, M., Kramer, V. G., Kurup, S., Zhan, P., Liu, X., Kongsted, J., & Byrareddy, S. N. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00843 · Cited by 191
Self-citationOverview of Recent Strategic Advances in Medicinal Chemistry
Wu, G., Zhao, T., Kang, D., Zhang, J., Song, Y., Namasivayam, V., Kongsted, J., Pannecouque, C., De Clercq, E., Poongavanam, V., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00359 · Cited by 181
Self-citationDevelopment of Safe Drugs: The hERG Challenge
Kalyaanamoorthy, S., & Barakat, K. H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21445 · Cited by 174
HIV Drug Resistance — An Emerging Threat to Epidemic Control
Beyrer, C., & Pozniak, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1710608 · Cited by 159
Kang, D., Fang, Z., Li, Z., Huang, B., Zhang, H., Lu, X., Xu, H., Zhou, Z., Ding, X., Daelemans, D., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00738 · Cited by 149
Self-citationMelikian, G., Rhee, S., Varghese, V., Porter, D., White, K., Taylor, J., Towner, W. J., Troia-Cancio, P. V., Burack, J. H., DeJesus, E., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt316 · Cited by 145
Ren, J., & STAMMERS, D. K. (2008) · Virus Research · doi:10.1016/j.virusres.2007.12.018 · Cited by 135
Cytochrome P450 research and The Journal of Biological Chemistry
Guengerich, F. P. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.tm118.004144 · Cited by 117
Avoiding drug resistance in HIV reverse transcriptase
Cilento, M. E., Kirby, K. A., & Sarafianos, S. G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00967 · Cited by 106 · cited 2×
“High levels of resistance can be rapidly induced by a single–amino acid point mutation, as exemplified by the two most prevalent single mutants: K103N and Y181C ( 10 , 11 ).”
Kang, D., Fang, Z., Huang, B., Lu, X., Zhang, H., Xu, H., Huo, Z., Zhou, Z., Zhao, Y., Meng, Q., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00332 · Cited by 101
Self-citationKang, D., Zhang, H., Wang, Z., Zhao, T., Ginex, T., Luque, F. J., Yang, Y., Wu, G., Feng, D., Wei, F., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01656 · Cited by 101
Self-citationSnapshot of the equilibrium dynamics of a drug bound to HIV-1 reverse transcriptase
Kuroda, D. G., Bauman, J. D., Challa, J. R., Patel, D., Troxler, T., Das, K., Arnold, E., & Hochstrasser, R. M. (2013) · Nature Chemistry · doi:10.1038/nchem.1559 · Cited by 97
Self-citationTambuyzer, L., Azijn, H., Rimsky, L. T., Vingerhoets, J., Lecocq, P., Kraus, G., Picchio, G., & de Béthune, M. (2009) · Antiviral Therapy · doi:10.1177/135965350901400114 · Cited by 93
Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design
Bauman, J. D., Das, K., Ho, W. C., Baweja, M., Himmel, D. M., Clark, A. D., Oren, D. A., Boyer, P. L., Hughes, S. H., Shatkin, A. J., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn464 · Cited by 88
Self-citationYang, Y., Kang, D., Nguyen, L. A., Smithline, Z. B., Pannecouque, C. C., Zhan, P., Liu, X., & Steitz, T. A. (2018) · eLife · doi:10.7554/elife.36340 · Cited by 84
Self-citationWang, Z., Cherukupalli, S., Xie, M., Wang, W., Jiang, X., Jia, R., Pannecouque, C. C., Clercq, E. D., Kang, D., Zhan, P., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01758 · Cited by 78
Self-citationA Structural View on Medicinal Chemistry Strategies against Drug Resistance
Agnello, S., Brand, M., Chellat, M. F., Gazzola, S., & Riedl, R. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201802416 · Cited by 74
Biochemical Mechanism of HIV-1 Resistance to Rilpivirine
Singh, K., Marchand, B., Rai, D. K., Sharma, B., Michailidis, E., Ryan, E. M., Matzek, K. B., Leslie, M. D., Hagedorn, A. N., Li, Z., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.398180 · Cited by 68
Architecture of an HIV-1 reverse transcriptase initiation complex
Larsen, K. P., Mathiharan, Y. K., Kappel, K., Coey, A. T., Chen, D.-H., Barrero, D., Madigan, L., Puglisi, J. D., Skiniotis, G., & Puglisi, E. V. (2018) · Nature · doi:10.1038/s41586-018-0055-9 · Cited by 66
PyVOL: a PyMOL plugin for visualization, comparison, and volume calculation of drug-binding sites
Smith, R. H. B., Dar, A. C., & Schlessinger, A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/816702 · Cited by 63
Molecular design opportunities presented by solvent‐exposed regions of target proteins
Jiang, X., Yu, J. H., Zhou, Z., Kongsted, J., Song, Y., Pannecouque, C. C., Clercq, E. D., Kang, D., Poongavanam, V., Liu, X., et al. (2019) · Medicinal Research Reviews · doi:10.1002/med.21581 · Cited by 62
Self-citationvan Welzen, B. J., van Lelyveld, S. F. L., ter Beest, G., Gisolf, J., Geerlings, S. E., Prins, J. M., Twillert, G. V., van Nieuwkoop, C., van der Valk, M., Burger, D. M., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae016 · Cited by 62
A Consistent Scheme for Gradient-Based Optimization of Protein – Ligand Poses
Flachsenberg, F., Meyder, A., Sommer, K., Penner, P., & Rarey, M. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01095 · Cited by 61
Betulinic Acid Derivatives as Human Immunodeficiency Virus Type 2 (HIV-2) Inhibitors
Dang, Z., Lai, W., Qian, K., Ho, P., Lee, K., Chen, C., & Huang, L. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9004253 · Cited by 58
Self-citationKang, D., Ruiz, F. X., Sun, Y., Feng, D., Jing, L., Wang, Z., Zhang, T., Gao, S., Sun, L., Clercq, E. D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00268 · Cited by 58
Self-citationBasson, A. E., Rhee, S., Parry, C. M., El‐Khatib, Z., Charalambous, S., de Oliveira, T., Pillay, D., Hoffmann, C. J., Katzenstein, D. A., Shafer, R. W., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04215-14 · Cited by 55
Gupta, S., Fransen, S., Paxinos, E. E., Stawiski, E. W., Huang, W., & Petropoulos, C. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00870-09 · Cited by 54
Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review
Havens, J. P., Podany, A. T., Scarsi, K. K., & Fletcher, C. V. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00830-9 · Cited by 53
Hombrouck, A., Voet, A., Van Remoortel, B., Desadeleer, C., De Maeyer, M., Debyser, Z., & Witvrouw, M. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00911-07 · Cited by 51
Structure of HIV-1 reverse transcriptase cleaving RNA in an RNA/DNA hybrid
Tian, L., Kim, M.-S., Li, H., Wang, J., & Yang, W. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719746115 · Cited by 51
HIV-1 uncoating requires long double-stranded reverse transcription products
Burdick, R. C., Morse, M., Rouzina, I. F., Williams, M. C., Hu, W.-S., & Pathak, V. K. (2024) · Science Advances · doi:10.1126/sciadv.adn7033 · Cited by 51
Ren, J., & STAMMERS, D. K. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.11.003 · Cited by 50
Ding, L., Zhuang, C., & Chen, F. (2021) · Medicinal Research Reviews · doi:10.1002/med.21760 · Cited by 49
Li, M., Passos, D. O., Shan, Z., Smith, S. J., Sun, Q., Biswas, A., Choudhuri, I., Strutzenberg, T. S., Haldane, A., Deng, N., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg5953 · Cited by 45
Structure of HIV-1 RT/dsRNA initiation complex prior to nucleotide incorporation
Das, K., Martinez, S. E., DeStefano, J. J., & Arnold, E. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814170116 · Cited by 41
Self-citationLiu, N., Wei, L., Huang, L., Yu, F., Zheng, W., Qin, B., Dong‐Qin, Z., Morris-Natschke, S. L., Jiang, S., Chen, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01827 · Cited by 38
Self-citationSoulié, C., Santoro, M. M., Charpentier, C., Storto, A., Paraskevis, D. N., Carlo, D. D., Gennari, W., D, G. S. M., Zazzi, M., Perno, C. F., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky464 · Cited by 34
Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
Himmel, D. M., & Arnold, E. (2020) · Pharmaceuticals · doi:10.3390/ph13060122 · Cited by 30
Self-citationSnoeck, J., Riva, C., Steegen, K., Schrooten, Y., Maes, B., Vergne, L., Laethem, K. V., Peeters, M., & Vandamme, A. (2005) · Journal of Virological Methods · doi:10.1016/j.jviromet.2005.04.001 · Cited by 28
Gray, W. T., Frey, K. M., Laskey, S. B., Mislak, A. C., Spasov, K. A., Lee, W., Bollini, M., Siliciano, R. F., Jorgensen, W. L., & Anderson, K. S. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00254 · Cited by 28
Gallien, S., Charreau, I., Néré, M. L., Mahjoub, N., Simon, F., Castro, N. D., Aboulker, J.-P., Molina, J., & Delaugerre, C. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku395 · Cited by 27
Ding, L., Pannecouque, C. C., Clercq, E. D., Zhuang, C., & Chen, F. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01676 · Cited by 26
Self-citationSoulié, C., Santoro, M. M., Storto, A., Abdi, B., Charpentier, C., Armenia, D., Jary, A., Forbici, F., Bertoli, A., Gennari, W., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz553 · Cited by 25
Integrative approaches in HIV ‐1 non‐nucleoside reverse transcriptase inhibitor design
Poongavanam, V., Namasivayam, V., Vanangamudi, M., Shamaileh, H. A., Veedu, R. N., Kihlberg, J. O., & Murugan, N. A. (2017) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1328 · Cited by 24
Future of nonnucleoside reverse transcriptase inhibitors
Sluis‐Cremer, N. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720975115 · Cited by 22
Lai, M., Munshi, V., Lu, M., Feng, M., Hrin, R. C., McKenna, P. M., Hazuda, D. J., & Miller, M. D. (2016) · Viruses · doi:10.3390/v8100263 · Cited by 20
Vrancken, B., Trovão, N. S., Baele, G., Wijngaerden, E. V., Vandamme, A., Laethem, K. V., & Lemey, P. (2016) · Viruses · doi:10.3390/v8010012 · Cited by 18
Brenner, B. G., Oliveira, M., Ibanescu, R.-I., Routy, J.-P., & Thomas, R. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad184 · Cited by 18
Jin, X., Zhao, L., Wang, S., Huang, W., Zhang, Y.-X., Pannecouque, C. C., Clercq, E. D., & Chen, F. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00468 · Cited by 16
Self-citationDiphoko, T., Gaseitsiwe, S., Kasvosve, I., Moyo, S. M., Okatch, H., Musonda, R. M., Wainberg, M. A., Makhema, J. M., Marlink, R., Novitsky, V., et al. (2018) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2017.0135 · Cited by 15
UNAIDS strategy aligns HIV priorities with development goals
The Lancet, H. I. V. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00075-8 · Cited by 12
The landscape and market for HIV therapies
Bowe, Z. G., Shanmugam, S., Hall-Thomsen, H., & Gubernick, S. I. (2023) · Nature Reviews Drug Discovery · doi:10.1038/d41573-023-00205-7 · Cited by 11
Aoki, M., Ogata-Aoki, H., Bulut, H., Hayashi, H., Takamune, N., Kishimoto, N., Tanaka, H., Higashi‐Kuwata, N., Hattori, S.-I., Das, D., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg2955 · Cited by 6
Cited by
Research progress on HIV-1 structural proteins and antiviral therapies
Wang, H., Yuan, J., & Wang, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805597 · Cited by 2
Quinoline derivatives as potential anti-cancer agents and their SARs elucidation
Wan, Y., Xiao, C., Jiayi, 张. Z., Wang, J., 周乐, Li, D., & Tang, Z. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146318 · Cited by 2
Zhang, Y.-X., Pannecouque, C. C., Clercq, E. D., Tramontano, E., Corona, A., Dettori, L., Tran, P., Li, X.-D., Su, S., Wang, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02556 · Cited by 1
Self-citationRecent Developments in HIV Antivirals: The Prospect of Prophylactic Drugs to Change the Pandemic
Brüssow, H. (2026) · Microbial Biotechnology · doi:10.1111/1751-7915.70317 · Cited by 1
Light-independent antimicrobial and acaricidal Ag/TiO₂ exhibited reduced allergenicity
Liu, X., Sun, J., Galluzzi, M., Zhong, H., Zhou, Z., & Chen, S. (2026) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-026-01793-9 · Cited by 1
Self-citation
Metadata
- Authors
- Wang, Z., Rumrill, S., Kang, D., Guma, S. D., Feng, D., De Clercq, E., Pannecouque, C., Chen, C. H., Arnold, E., Ruiz, F. X., Liu, X., & Zhan, P.
- Affiliations
- Shandong University (CN)
- Rutgers, The State University of New Jersey (US)
- Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, K.U. Leuven, Herestraat 49 Postbus 1043 (09.A097), B-3000 Leuven, Belgium.
- Rega Institute for Medical Research (BE)
- Duke Medical Center (US)
- Corresponding author
- Wang, Zhao
- Rumrill, Shawn
- Kang, Dongwei
- Guma, Samuel Desta
- Chen, Chin Ho
- Arnold, Eddy
- Ruiz, Francesc Xavier
- Liu, Xinyong
- Zhan, Peng
- ORCID
- Venue
- Science Advances
- Published
- 2025-05-30
- Volume
- 11
- Issue
- 22
- Pages
- eadt8916-eadt8916
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC12124364
- OpenAlex
- W4410886466
- Cited by
- 7
- References
- 74
- Citations by year
- 2026: 6 · 2025: 1
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Lirias (submittedVersion, cc-by-nc)
- Funders
- Shandong University (SYS202205)
- Ministry of Science and Technology of the People's Republic of China (2019ZX09301-126)
- Natural Science Foundation of Shandong Province (ZR2020JQ31, ZR2020YQ61)
- National Institutes of Health
- National Institute of General Medical Sciences (GM135141, GM008339, T32GM008339)
- National Institute of Allergy and Infectious Diseases (R01AI027690)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- HIV-1, non-nucleoside reverse transcriptase inhibitors, drug resistance, reverse transcriptase, structure-based drug design, scaffold hopping, antiviral efficacy, pharmacokinetics, oral bioavailability, cytochrome P450 inhibition, co-crystal structure, conformational flexibility
- MeSH terms
- Rilpivirine, Animals, Humans, Microbial Sensitivity Tests, Mutation, Structure-Activity Relationship, HIV-1, HIV Infections, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Drug Resistance, Viral, HIV Reverse Transcriptase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.